Company Overview of Constellation Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops drugs in the field of epigenetics. The company develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders, and other diseases. Its drug discovery and development platform creates a pipeline of programs across the writer, eraser, and reader classes of epigenetic targets to develop new drugs in oncology, inflammation, and other therapeutic areas. Constellation Pharmaceuticals, Inc. has a strategic agreement with Genentech. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in April 2008. Constellation Phar...
215 First Street
Cambridge, MA 02142
Founded in 2008
Key Executives for Constellation Pharmaceuticals, Inc.
Chief Executive Officer and President
Compensation as of Fiscal Year 2013.
Constellation Pharmaceuticals, Inc. Key Developments
Constellation Pharmaceuticals, Inc. Announces New Preclinical Data on Novel Bet Bromodomain Inhibitors
Oct 8 13
Constellation Pharmaceuticals, Inc. announced the publication of a study in the Journal of Experimental Medicine demonstrating that small molecule inhibitors selectively targeting BET bromodomains can suppress T helper 17 (T 17) differentiation and T 17-mediated pathology in models of autoimmune diseases. The paper appears in the online early edition of J Exp Med published on October 7, 2013. During the last decade, researchers have uncovered the importance of T 17 cells as an integral part of the immune system that protects the human body from infections. However, this research has also shown that, when pathologically activated, these cells can attack multiple organs in the body and trigger autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. Because of the important roles that T 17 cells play in both normal and dysregulated immune function, many academic, biotech and pharmaceutical laboratories have research programs devoted to targeting T 17 cells.
Constellation Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's East/West CEO Conference, Jan-06-2013 12:15 PM
Jan 4 13
Constellation Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's East/West CEO Conference, Jan-06-2013 12:15 PM. Venue: Four Seasons Hotel, San Francisco, California, United States. Speakers: Keith E. Dionne, Chief Executive Officer and President.
Constellation Pharmaceuticals, Inc. Enter into Strategic Partnership with The Leukemia & Lymphoma Society to Develop Novel Bet Inhibitor for the Treatment of Hematologic Malignancies
Sep 20 12
Constellation Pharmaceuticals, Inc. announced that it has entered into a strategic partnership with The Leukemia & Lymphoma Society(R) (LLS) to advance the development of a novel BET inhibitor for the treatment of patients with hematologic malignancies. Under the terms of the agreement, LLS will provide up to $7.5 million in funding to support Constellation's small molecule BET inhibitor program through the completion of a broad Phase 1 clinical plan. Taking an active role in accelerating development of novel therapies for patients, the LLS have committed funding to support this collaboration as part of its Therapy Acceleration Program (TAP). TAP is LLS's bold initiative designed to advance therapies with high prospects of providing benefit to patients suffering from blood cancers. By partnering directly with biotechnology companies, LLS is taking a results-oriented approach to more quickly identify potential breakthrough therapies and advance them along the FDA drug approval pathway.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|